Telomerase Activity in Well-Differentiated Papillary Thyroid Carcinoma Correlates with Advanced Clinical Stage of the Disease

Endocrine Pathology

Volumn 14, Issue 3, 2003, Pages 213-219

  Bornstein Quevedo, Leticia ^a   Garcia Hernandez M L ^a   Camacho Arroyo, Ignacio ^b   Herrera, Miguel F ^a   Angeles, Arturo Angeles ^a   Treviño, Ofelia González ^a   Gamboa Domínguez, Armando ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Clinical stage; Papillary thyroid carcinoma; pTNM; Telomerase activity; TRAP age; Tumor progression

Indexed keywords

TELOMERASE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER STAGING; ENZYME ACTIVITY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; THYROID CARCINOMA; THYROID PAPILLARY CARCINOMA;

ADULT; CARCINOMA, PAPILLARY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; TELOMERASE; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 0242288591     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1385/EP:14:3:213     Document Type: Article

References (26)

1. Schlumberger M. Papillary and follicular thyroid carcinoma. N Eng J Med 338:297-306, 1998.
2. Wang C, Grapo LM. The epidemiology of thyroid disease and implications for screening. Endocrinol Clin North Am 26:189-218, 1997.
3. Sobin LH, Wittekind CH. TNM classification of malignant tumours. 5th ed. Berlin, Germany: Springer-Verlag, 1997.
4. Hay ID, Grant CS, Taylor WE, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 102:1088-1095, 1997.
5. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predictive outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114:1050-1057, 1993.
6. Sanders LE, Cady B. Differentiated thyroid cancer: reexamination of risk groups and outcome of treatment. Arch Surg 133:419-425, 1998.
7. Loh KC, Greenspan FS, Gee L, Miller TR, Yeo PP. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab 82:3553-3562, 1997.
8. Bongarzone I, Fugazzola L, Vigncri P, et al. Age-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinoma. J Clin Endocrinol Metab 81:2006-2009, 1996.
9. Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454-1457, 2003.
10. La Perle KM, Jhiang SM, Capen CC. Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas. Am J Pathol 157:671-677, 2000.
11. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011-2014, 1994.
12. Weinrich SL, Pruzan R, Ma L, et al. Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat Genet 17:498-502, 1997.
13. Brousset P, Chaouche N, Leprat F, et al. Telomerase activity in human thyroid carcinomas originating from the follicular cells. J Clin Endocrinol Metab 82:4214-4216, 1997.
14. Aogi K, Kitahara K, Buley I. Telomerase activity in lesions of the thyroid application to diagnosis and clinical samples of fine-needle aspirates. Clin Cancer Res 4:1965-1970, 1998.
15. Haugen BR, Nawaz S, Markham N, et al. Telomerase activity in benign and malignant thyroid tumors. Thyroid 7:337-342, 1997.
16. Yashima K, Vuitch F, Gazdar AF, Fahey TJ. Telomerase activity in benign and malignant thyroid diseases. Surgery 122:1141-1146, 1997.
17. Cheng AJ, Lin JD, Chang T, Wang TCV. Telomerase activity in benign and malignant human thyroid tissues. Br J Cancer 77:2177-2180, 1998.
18. Hedinger Chr, Williams ED, Sobin LH. Histological typing of thyroid tumors. 2nd ed. Berlin: Springer-Verlag, 1993.
19. Greene FL, Page DL, Fleming ID, et al. AJCC cancer staging manual. 6th ed. New York: Springer-Verlag, 2003.
20. Bradford MM. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254, 1976.
21. Onada M, Ishikawa T, Yoshikawa K, Telomerase activity in thyroid tumors. Oncol Rep 5:1447-1450, 1998.
22. Counter CM, Avilion AA, LeFeuvre CE, et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 11:1921-1929, 1992.
23. Matthews P, Jones CJ, Skinner J, Haughton M, de Micco C, Wyndford Thomas D. Telomerase activity and telomere length in thyroid neoplasia: biological and clinical implications. J Pathol 194:183-193, 2001.
24. Bryan TM, Englezou A, Dalla-Pozza L, et al. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 3:1271-1274, 1997.
25. Harrington L, McPhail T, Mar V. A mammalian telomerase-associated protein. Science 275:973-977, 1997
26. Mergny JL, Riou JF, Mailliet P, Teulade-Fichou MP, Gilson E. Natural and pharmacological regulation of telomerase. Nucleic Acids Res 30:839-865, 2002.